TISSIUM develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.
TISSIUM has raised $34.0M in total funding. The most recent round was Series D. The last funding was announced in June 2026.
TISSIUM's investors include European Investment Bank, Bpifrance, Cathay Capital, BNP Paribas, Sofinnova Partners.
TISSIUM is headquartered in Paris, France.
TISSIUM develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.
TISSIUM is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TISSIUM — Funding & Investors." VCBacked, June 24, 2026, https://www.vcbacked.co/company/tissium. Accessed November 13, 2026.
VCBacked. (2026). TISSIUM — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/tissium
{{cite web |title=TISSIUM — Funding & Investors |url=https://www.vcbacked.co/company/tissium |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at TISSIUM? Request a listing update